Abstract
OBJECTIVE: To evaluate the clinical efficacy and lipid metabolism impact of intensified treatment with degludec-aspart dual insulin combined with semaglutide in patients with type 2 diabetes. METHODS: A systematic comparison and analysis were conducted on the changes in glycolipid metabolism-related indicators (including fasting blood glucose, glycated hemoglobin, fructosamine, and 2-hour postprandial blood glucose), blood glucose fluctuation indicators (specifically including standard deviation of blood glucose, postprandial blood glucose fluctuation amplitude, and 24-hour average blood glucose), insulin function status indicators (serum insulin level, fasting C-peptide (FCP), and 2-hour postprandial C-peptide (2hCP)), insulin resistance index, visceral fat index, and lipid index (including total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol) between the two groups of patients. Additionally, the adverse reactions and their incidence rates during the treatment period were statistically analyzed. RESULTS: Before treatment, there was no significant difference in glycolipid metabolism indicators, blood glucose fluctuation, insulin function and resistance index, visceral fat index, or lipid indicators between the two groups (all P > 0.05). After treatment, these indicators in both groups improved compared to before treatment, and the observation group showed significantly better outcomes than the control group (all P < 0.05). Moreover, there was no =significant difference in the incidence of adverse reactions between groups (P=0.576). CONCLUSION: Intensified treatment with degludec-aspart dual insulin combined with semaglutide could improve blood glucose control, enhance insulin function, stabilize lipid levels, and did not increase treatment-related adverse reactions.